NgJacqi的个人主页 - 老虎社区

NgJacqi

NgJacqi

暂无个人介绍

IP属地：未知

15关注

1粉丝

0主题

0勋章

2021-09-19

Nice

How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?

2021-07-22

Oh

How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?

2021-07-16

Oh

Airlines stocks gains in early trading, as Biden Hinting at Lifting Europe Travel Ban.

2021-06-16

Mm

抱歉，原内容已删除

2021-05-25

[Smile]

抱歉，原内容已删除

2021-04-29

Mm

抱歉，原内容已删除

2021-04-29

.

Uber app in U.S. to enable users to book vaccines and rental cars

2021-04-22

H

Why Square And Cathie Wood's Ark See Bitcoin Environmental Concerns As Unfounded

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3580907067323762","uuid":"3580907067323762","gmtCreate":1617813043092,"gmtModify":1619662698698,"name":"NgJacqi","pinyin":"ngjacqi","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":15,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":887583775,"gmtCreate":1632064306797,"gmtModify":1632803059679,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/887583775","repostId":"2153678132","repostType":4,"repost":{"id":"2153678132","pubTimestamp":1626958620,"share":"https://www.laohu8.com/m/news/2153678132?lang=&edition=full","pubTime":"2021-07-22 20:57","market":"us","language":"en","title":"How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2153678132","media":"Motley Fool","summary":"There are four possible answers.","content":"<p><b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> currently has <a href=\"https://laohu8.com/S/AONE.U\">one</a> product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of which will advance into late-stage clinical studies this year</p>\n<p><b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.</p>\n<p>Pfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.</p>\n<p>Now for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?</p>\n<p><img src=\"https://static.tigerbbs.com/87bb195f09ece4498c77c8942205e5a8\" tg-width=\"700\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Four possibilities</h3>\n<p>There are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:</p>\n<ol>\n <li>Moderna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.</li>\n <li>Moderna stock is overvalued.</li>\n <li>Pfizer stock is undervalued.</li>\n <li>Both No. 2 and No. 3 above are true.</li>\n</ol>\n<p>If you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.</p>\n<p>Some investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.</p>\n<p>My view is similar to the one held by Warren Buffett's mentor, Benjamin <a href=\"https://laohu8.com/S/GHC\">Graham</a>. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.</p>\n<h3>The best answer</h3>\n<p>I have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the <b>S&amp;P 500</b> average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.</p>\n<p>Part of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.</p>\n<p>The key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.</p>\n<p>However,&nbsp;I suspect that investors could be overly exuberant about the company's inclusion on the S&amp;P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.</p>\n<p>In my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.</p>\n<h3>A temporary situation</h3>\n<p>When a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.</p>\n<p>On the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.</p>\n<p>I don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153678132","content_text":"Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, one of which will advance into late-stage clinical studies this year\nPfizer is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.\nPfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.\nNow for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?\n\nImage source: Getty Images.\nFour possibilities\nThere are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:\n\nModerna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.\nModerna stock is overvalued.\nPfizer stock is undervalued.\nBoth No. 2 and No. 3 above are true.\n\nIf you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.\nSome investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.\nMy view is similar to the one held by Warren Buffett's mentor, Benjamin Graham. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.\nThe best answer\nI have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the S&P 500 average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.\nPart of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.\nThe key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.\nHowever, I suspect that investors could be overly exuberant about the company's inclusion on the S&P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.\nIn my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.\nA temporary situation\nWhen a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.\nOn the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.\nI don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172623653,"gmtCreate":1626959806072,"gmtModify":1633769379648,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/172623653","repostId":"2153678132","repostType":4,"repost":{"id":"2153678132","pubTimestamp":1626958620,"share":"https://www.laohu8.com/m/news/2153678132?lang=&edition=full","pubTime":"2021-07-22 20:57","market":"us","language":"en","title":"How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2153678132","media":"Motley Fool","summary":"There are four possible answers.","content":"<p><b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> currently has <a href=\"https://laohu8.com/S/AONE.U\">one</a> product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of which will advance into late-stage clinical studies this year</p>\n<p><b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.</p>\n<p>Pfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.</p>\n<p>Now for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?</p>\n<p><img src=\"https://static.tigerbbs.com/87bb195f09ece4498c77c8942205e5a8\" tg-width=\"700\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Four possibilities</h3>\n<p>There are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:</p>\n<ol>\n <li>Moderna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.</li>\n <li>Moderna stock is overvalued.</li>\n <li>Pfizer stock is undervalued.</li>\n <li>Both No. 2 and No. 3 above are true.</li>\n</ol>\n<p>If you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.</p>\n<p>Some investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.</p>\n<p>My view is similar to the one held by Warren Buffett's mentor, Benjamin <a href=\"https://laohu8.com/S/GHC\">Graham</a>. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.</p>\n<h3>The best answer</h3>\n<p>I have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the <b>S&amp;P 500</b> average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.</p>\n<p>Part of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.</p>\n<p>The key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.</p>\n<p>However,&nbsp;I suspect that investors could be overly exuberant about the company's inclusion on the S&amp;P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.</p>\n<p>In my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.</p>\n<h3>A temporary situation</h3>\n<p>When a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.</p>\n<p>On the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.</p>\n<p>I don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153678132","content_text":"Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, one of which will advance into late-stage clinical studies this year\nPfizer is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.\nPfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.\nNow for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?\n\nImage source: Getty Images.\nFour possibilities\nThere are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:\n\nModerna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.\nModerna stock is overvalued.\nPfizer stock is undervalued.\nBoth No. 2 and No. 3 above are true.\n\nIf you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.\nSome investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.\nMy view is similar to the one held by Warren Buffett's mentor, Benjamin Graham. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.\nThe best answer\nI have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the S&P 500 average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.\nPart of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.\nThe key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.\nHowever, I suspect that investors could be overly exuberant about the company's inclusion on the S&P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.\nIn my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.\nA temporary situation\nWhen a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.\nOn the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.\nI don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170402048,"gmtCreate":1626444496184,"gmtModify":1633926680652,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/170402048","repostId":"1119997447","repostType":4,"repost":{"id":"1119997447","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626443027,"share":"https://www.laohu8.com/m/news/1119997447?lang=&edition=full","pubTime":"2021-07-16 21:43","market":"us","language":"en","title":"Airlines stocks gains in early trading, as Biden Hinting at Lifting Europe Travel Ban.","url":"https://stock-news.laohu8.com/highlight/detail?id=1119997447","media":"Tiger Newspress","summary":"Airlines stocks gains in early trading, as Biden Hinting at Lifting Europe Travel Ban.\nUAL and DAL s","content":"<p>Airlines&nbsp;stocks&nbsp;gains&nbsp;in&nbsp;early&nbsp;trading,&nbsp;as&nbsp;Biden Hinting at Lifting Europe Travel Ban.</p>\n<p>UAL&nbsp;and&nbsp;DAL&nbsp;shares&nbsp;rise&nbsp;more&nbsp;than&nbsp;1%,AAL&nbsp;is&nbsp;up&nbsp;0.5%.</p>\n<p><img src=\"https://static.tigerbbs.com/00597dcb6aef11ef28bb4c12d2240db1\" tg-width=\"1284\" tg-height=\"592\" referrerpolicy=\"no-referrer\">U.S. President Joe Biden signaled progress toward lifting a ban on travel from Europe, raising hopes for a reopening of the almost $40 billion North Atlantic air corridor 16 months after flights were grounded by Covid-19.</p>\n<p>“It’s in process now,” Biden said at a news conference with Merkel following their meeting. “I’m waiting to hear from our folks, our Covid team, as to when that should be done.”</p>\n<p>He said to expect an answer “within the next several days.”</p>\n<p>Removing the ban would be a boon for carriers on both sides of the Atlantic. Former President Donald Trump barred entry from most of Europe, including the U.K., in March 2020, and Biden extended the policy early in his term.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Airlines stocks gains in early trading, as Biden Hinting at Lifting Europe Travel Ban.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAirlines stocks gains in early trading, as Biden Hinting at Lifting Europe Travel Ban.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-16 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Airlines&nbsp;stocks&nbsp;gains&nbsp;in&nbsp;early&nbsp;trading,&nbsp;as&nbsp;Biden Hinting at Lifting Europe Travel Ban.</p>\n<p>UAL&nbsp;and&nbsp;DAL&nbsp;shares&nbsp;rise&nbsp;more&nbsp;than&nbsp;1%,AAL&nbsp;is&nbsp;up&nbsp;0.5%.</p>\n<p><img src=\"https://static.tigerbbs.com/00597dcb6aef11ef28bb4c12d2240db1\" tg-width=\"1284\" tg-height=\"592\" referrerpolicy=\"no-referrer\">U.S. President Joe Biden signaled progress toward lifting a ban on travel from Europe, raising hopes for a reopening of the almost $40 billion North Atlantic air corridor 16 months after flights were grounded by Covid-19.</p>\n<p>“It’s in process now,” Biden said at a news conference with Merkel following their meeting. “I’m waiting to hear from our folks, our Covid team, as to when that should be done.”</p>\n<p>He said to expect an answer “within the next several days.”</p>\n<p>Removing the ban would be a boon for carriers on both sides of the Atlantic. Former President Donald Trump barred entry from most of Europe, including the U.K., in March 2020, and Biden extended the policy early in his term.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UAL":"联合大陆航空","AAL":"美国航空","DAL":"达美航空","LUV":"西南航空"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119997447","content_text":"Airlines stocks gains in early trading, as Biden Hinting at Lifting Europe Travel Ban.\nUAL and DAL shares rise more than 1%,AAL is up 0.5%.\nU.S. President Joe Biden signaled progress toward lifting a ban on travel from Europe, raising hopes for a reopening of the almost $40 billion North Atlantic air corridor 16 months after flights were grounded by Covid-19.\n“It’s in process now,” Biden said at a news conference with Merkel following their meeting. “I’m waiting to hear from our folks, our Covid team, as to when that should be done.”\nHe said to expect an answer “within the next several days.”\nRemoving the ban would be a boon for carriers on both sides of the Atlantic. Former President Donald Trump barred entry from most of Europe, including the U.K., in March 2020, and Biden extended the policy early in his term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":113,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169587962,"gmtCreate":1623843384456,"gmtModify":1634027254321,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Mm","listText":"Mm","text":"Mm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/169587962","repostId":"2143795927","repostType":4,"isVote":1,"tweetType":1,"viewCount":260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":131418321,"gmtCreate":1621873093863,"gmtModify":1634185888751,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/131418321","repostId":"2137153015","repostType":4,"isVote":1,"tweetType":1,"viewCount":250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":100439171,"gmtCreate":1619627192393,"gmtModify":1634211204688,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Mm","listText":"Mm","text":"Mm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/100439171","repostId":"1104198438","repostType":4,"isVote":1,"tweetType":1,"viewCount":370,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":100430961,"gmtCreate":1619627089353,"gmtModify":1634211205061,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/100430961","repostId":"1196474090","repostType":4,"repost":{"id":"1196474090","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1619623392,"share":"https://www.laohu8.com/m/news/1196474090?lang=&edition=full","pubTime":"2021-04-28 23:23","market":"us","language":"en","title":"Uber app in U.S. to enable users to book vaccines and rental cars","url":"https://stock-news.laohu8.com/highlight/detail?id=1196474090","media":"Reuters","summary":"Uber Technologies Inc said on Wednesday it was launching new features in its app to allow U.S. custo","content":"<p>Uber Technologies Inc said on Wednesday it was launching new features in its app to allow U.S. customers to book COVID-19 vaccine appointments and reserve rental cars.</p>\n<p>Customers would be able reserve an appointment at a Walgreens pharmacy to receive a vaccine and book an Uber ride to travel there, the firm said in a product presentation.</p>\n<p>The feature, which expands an Uber and Walgreens partnership announced in February, reflects the wider availability of COVID-19 inoculations in the United States, where every state has opened up vaccines to all adults.</p>\n<p>For Uber, more vaccinations mean a quicker return to pre-pandemic travel and higher revenues, which tumbled during the pandemic. The number of journeys has already increased. March was the best month since the pandemic's full force was felt.</p>\n<p>The company also announced partnerships with Avis Budget Group Inc, Hertz and other vehicle rental agencies.</p>\n<p>From Wednesday, U.S. customers can book rental cars through the Uber app, with Uber offering up to 10% of the rental cost as a credit to the user to spend on other Uber services.</p>\n<p>In May, users in Washington DC can have their rental car delivered to and collected from their home, after paying a fee to Uber, which will rollout the service nationwide this year.</p>\n<p>Uber's smaller rival Lyft Inc already offers car rentals in partnership with Sixt SE.</p>\n<p>Uber also said it would expand an option to reserve rides in advance to more U.S. and European cities and allow customers to book and collect food delivery orders during a ride-hail trip.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Uber app in U.S. to enable users to book vaccines and rental cars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUber app in U.S. to enable users to book vaccines and rental cars\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-04-28 23:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Uber Technologies Inc said on Wednesday it was launching new features in its app to allow U.S. customers to book COVID-19 vaccine appointments and reserve rental cars.</p>\n<p>Customers would be able reserve an appointment at a Walgreens pharmacy to receive a vaccine and book an Uber ride to travel there, the firm said in a product presentation.</p>\n<p>The feature, which expands an Uber and Walgreens partnership announced in February, reflects the wider availability of COVID-19 inoculations in the United States, where every state has opened up vaccines to all adults.</p>\n<p>For Uber, more vaccinations mean a quicker return to pre-pandemic travel and higher revenues, which tumbled during the pandemic. The number of journeys has already increased. March was the best month since the pandemic's full force was felt.</p>\n<p>The company also announced partnerships with Avis Budget Group Inc, Hertz and other vehicle rental agencies.</p>\n<p>From Wednesday, U.S. customers can book rental cars through the Uber app, with Uber offering up to 10% of the rental cost as a credit to the user to spend on other Uber services.</p>\n<p>In May, users in Washington DC can have their rental car delivered to and collected from their home, after paying a fee to Uber, which will rollout the service nationwide this year.</p>\n<p>Uber's smaller rival Lyft Inc already offers car rentals in partnership with Sixt SE.</p>\n<p>Uber also said it would expand an option to reserve rides in advance to more U.S. and European cities and allow customers to book and collect food delivery orders during a ride-hail trip.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UBER":"优步"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196474090","content_text":"Uber Technologies Inc said on Wednesday it was launching new features in its app to allow U.S. customers to book COVID-19 vaccine appointments and reserve rental cars.\nCustomers would be able reserve an appointment at a Walgreens pharmacy to receive a vaccine and book an Uber ride to travel there, the firm said in a product presentation.\nThe feature, which expands an Uber and Walgreens partnership announced in February, reflects the wider availability of COVID-19 inoculations in the United States, where every state has opened up vaccines to all adults.\nFor Uber, more vaccinations mean a quicker return to pre-pandemic travel and higher revenues, which tumbled during the pandemic. The number of journeys has already increased. March was the best month since the pandemic's full force was felt.\nThe company also announced partnerships with Avis Budget Group Inc, Hertz and other vehicle rental agencies.\nFrom Wednesday, U.S. customers can book rental cars through the Uber app, with Uber offering up to 10% of the rental cost as a credit to the user to spend on other Uber services.\nIn May, users in Washington DC can have their rental car delivered to and collected from their home, after paying a fee to Uber, which will rollout the service nationwide this year.\nUber's smaller rival Lyft Inc already offers car rentals in partnership with Sixt SE.\nUber also said it would expand an option to reserve rides in advance to more U.S. and European cities and allow customers to book and collect food delivery orders during a ride-hail trip.","news_type":1},"isVote":1,"tweetType":1,"viewCount":268,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":376955276,"gmtCreate":1619083157295,"gmtModify":1634288694301,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"H","listText":"H","text":"H","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/376955276","repostId":"1134663439","repostType":4,"repost":{"id":"1134663439","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1619082614,"share":"https://www.laohu8.com/m/news/1134663439?lang=&edition=full","pubTime":"2021-04-22 17:10","market":"us","language":"en","title":"Why Square And Cathie Wood's Ark See Bitcoin Environmental Concerns As Unfounded","url":"https://stock-news.laohu8.com/highlight/detail?id=1134663439","media":"Benzinga","summary":"Cathie Wood-led Ark Investment Management and digital payment company Square Inc.(NYSE:SQ) have team","content":"<p>Cathie Wood-led&nbsp;<b>Ark Investment Management</b>&nbsp;and digital payment company&nbsp;<b>Square Inc.</b>(NYSE:SQ) have teamed up to dispel the notion thatBitcoin(BTC) mining is damaging the environment.</p><p><b>What Happened:</b>&nbsp;Ark Investment and Jack Dorsey-led Squarereleaseda whitepaper arguing that Bitcoin mining provides an opportunity to spur the global energy transition to renewables by serving as a complementary technology for clean energy production and storage.</p><p>“Combining generation with both storage and miners presents a better overall value proposition than building generation and storage alone,” the companies noted.</p><p>The companies believe that Bitcoin miners as a flexible and easily interruptible load option could likely solve the intermittency and grid congestion problems hampering the deployment of solar and wind energy, which are now the cheapest energy sources in the world.</p><p>The combination of miners with renewable and storage projects could improve the returns for project investors, allow for the construction of solar and wind projects even before the completion of lengthy grid interconnection studies, and provide the grid with readily available “excess” energy, according to the paper.</p><p>“The bitcoin and energy markets are converging and we believe the energy asset owners of today will likely become the miners of tomorrow,” the companies concluded.</p><p>Square is heavily invested&nbsp;in Bitcoin.&nbsp;Cathie Wood is also bullish on cryptocurrencies and hasacquired sharesin cryptocurrency exchange<b>Coinbase Global Inc.</b>(NASDAQ:COIN), which recently made its debut on the Nasdaq stock exchange.</p><p><b>Why It Matters:</b>&nbsp;The release of the research paper comes amid arguments that Bitcoin causes tons of carbon emissions and environmental degradation<b>.</b></p><p>Bank of America analyst Francisco Blanchcriticized Bitcoin&nbsp;in March, noting that the Bitcoin network emits about 60 million tons of CO2 annually, roughly the same carbon footprint as the nation of Greece.</p><p>For every $1 billion of fresh inflow into bitcoin, Blanch estimates the cryptocurrency will generate additional CO2 levels equivalent to about 1.2 million cars with internal combustion engines.</p><p><b>Microsoft Corporation</b>&nbsp;(NASDAQ:MSFT) founder Bill Gates has also expressed concerns about Bitcoin’s impact on climate change,notingin February that the cryptocurrency “uses more electricity per transaction than any other method known to mankind.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Square And Cathie Wood's Ark See Bitcoin Environmental Concerns As Unfounded</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Square And Cathie Wood's Ark See Bitcoin Environmental Concerns As Unfounded\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-04-22 17:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Cathie Wood-led&nbsp;<b>Ark Investment Management</b>&nbsp;and digital payment company&nbsp;<b>Square Inc.</b>(NYSE:SQ) have teamed up to dispel the notion thatBitcoin(BTC) mining is damaging the environment.</p><p><b>What Happened:</b>&nbsp;Ark Investment and Jack Dorsey-led Squarereleaseda whitepaper arguing that Bitcoin mining provides an opportunity to spur the global energy transition to renewables by serving as a complementary technology for clean energy production and storage.</p><p>“Combining generation with both storage and miners presents a better overall value proposition than building generation and storage alone,” the companies noted.</p><p>The companies believe that Bitcoin miners as a flexible and easily interruptible load option could likely solve the intermittency and grid congestion problems hampering the deployment of solar and wind energy, which are now the cheapest energy sources in the world.</p><p>The combination of miners with renewable and storage projects could improve the returns for project investors, allow for the construction of solar and wind projects even before the completion of lengthy grid interconnection studies, and provide the grid with readily available “excess” energy, according to the paper.</p><p>“The bitcoin and energy markets are converging and we believe the energy asset owners of today will likely become the miners of tomorrow,” the companies concluded.</p><p>Square is heavily invested&nbsp;in Bitcoin.&nbsp;Cathie Wood is also bullish on cryptocurrencies and hasacquired sharesin cryptocurrency exchange<b>Coinbase Global Inc.</b>(NASDAQ:COIN), which recently made its debut on the Nasdaq stock exchange.</p><p><b>Why It Matters:</b>&nbsp;The release of the research paper comes amid arguments that Bitcoin causes tons of carbon emissions and environmental degradation<b>.</b></p><p>Bank of America analyst Francisco Blanchcriticized Bitcoin&nbsp;in March, noting that the Bitcoin network emits about 60 million tons of CO2 annually, roughly the same carbon footprint as the nation of Greece.</p><p>For every $1 billion of fresh inflow into bitcoin, Blanch estimates the cryptocurrency will generate additional CO2 levels equivalent to about 1.2 million cars with internal combustion engines.</p><p><b>Microsoft Corporation</b>&nbsp;(NASDAQ:MSFT) founder Bill Gates has also expressed concerns about Bitcoin’s impact on climate change,notingin February that the cryptocurrency “uses more electricity per transaction than any other method known to mankind.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134663439","content_text":"Cathie Wood-led Ark Investment Management and digital payment company Square Inc.(NYSE:SQ) have teamed up to dispel the notion thatBitcoin(BTC) mining is damaging the environment.What Happened: Ark Investment and Jack Dorsey-led Squarereleaseda whitepaper arguing that Bitcoin mining provides an opportunity to spur the global energy transition to renewables by serving as a complementary technology for clean energy production and storage.“Combining generation with both storage and miners presents a better overall value proposition than building generation and storage alone,” the companies noted.The companies believe that Bitcoin miners as a flexible and easily interruptible load option could likely solve the intermittency and grid congestion problems hampering the deployment of solar and wind energy, which are now the cheapest energy sources in the world.The combination of miners with renewable and storage projects could improve the returns for project investors, allow for the construction of solar and wind projects even before the completion of lengthy grid interconnection studies, and provide the grid with readily available “excess” energy, according to the paper.“The bitcoin and energy markets are converging and we believe the energy asset owners of today will likely become the miners of tomorrow,” the companies concluded.Square is heavily invested in Bitcoin. Cathie Wood is also bullish on cryptocurrencies and hasacquired sharesin cryptocurrency exchangeCoinbase Global Inc.(NASDAQ:COIN), which recently made its debut on the Nasdaq stock exchange.Why It Matters: The release of the research paper comes amid arguments that Bitcoin causes tons of carbon emissions and environmental degradation.Bank of America analyst Francisco Blanchcriticized Bitcoin in March, noting that the Bitcoin network emits about 60 million tons of CO2 annually, roughly the same carbon footprint as the nation of Greece.For every $1 billion of fresh inflow into bitcoin, Blanch estimates the cryptocurrency will generate additional CO2 levels equivalent to about 1.2 million cars with internal combustion engines.Microsoft Corporation (NASDAQ:MSFT) founder Bill Gates has also expressed concerns about Bitcoin’s impact on climate change,notingin February that the cryptocurrency “uses more electricity per transaction than any other method known to mankind.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":332,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":169587962,"gmtCreate":1623843384456,"gmtModify":1634027254321,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Mm","listText":"Mm","text":"Mm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/169587962","repostId":"2143795927","repostType":4,"repost":{"id":"2143795927","pubTimestamp":1623840600,"share":"https://www.laohu8.com/m/news/2143795927?lang=&edition=full","pubTime":"2021-06-16 18:50","market":"us","language":"en","title":"Bright Minds Biosciences Announces Application to List on Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2143795927","media":"StreetInsider","summary":"VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Min","content":"<p>VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain, is pleased to announce that it has submitted an application to list on The Nasdaq Stock Market (“Nasdaq”). The Company has reserved the right to trade under the symbol “DRUG.”</p>\n<p>Commenting on the plans for the Nasdaq listing, Ian McDonald, Chief Executive Officer of Bright Minds, said, “We believe that this is an ideal time for Bright Minds to announce its plans to move to a leading national stock exchange. Serotonergic therapeutics have gained considerable traction and are on the cusp of an exciting revolution in medicine. BMB is already moving to the clinic with a patented 5-HT2C drug for use in epilepsy. Moreover, having developed a robust pipeline of novel, best-in-class 5-HT2A/2C (serotonin) agonists that refine and build on the first-generation natural compound approaches, Bright Minds has laid a solid foundation to become the front runner in psychedelic-drug inspired medicine. We are very excited to list on the Nasdaq and see it as a critical step in our evolution as a public company. The additional capital markets exposure will elevate our company profile with the biotechnology investment community, broaden and diversify our investor base, and most importantly, continue to support our efforts to design and develop next-generation therapeutics that address difficult-to-treat indications across mental health disorders, epilepsy and pain management.”</p>\n<p>In advance of an anticipated listing on Nasdaq, Bright Minds has filed a Registration Statement with the United States Securities and Exchange Commission. The listing of Common Shares on Nasdaq remains subject to the review and approval of the listing application and the satisfaction of all applicable listing and regulatory requirements, as well as the effectiveness of the registration statement. Bright Minds will continue to maintain the listing of its Shares on the Canadian Stock Exchange under the symbol “DRUG.”</p>\n<p>Bright Minds also announced that it has granted an aggregate of 180,000 stock options (the “Options”) to a director and a consultant of the Company to purchase 180,000 common shares (the “Shares”) in the capital of the Company pursuant to the Company’s share option plan. The Options are exercisable at an exercise price of $7.60 per Share for a period of five (5) years from the date of grant. The Options are subject to vesting periods over the course of the term of the Options.</p>\n<p>The securities of the Company referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “<b>U.S. Securities Act</b>”), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation, or sale would be unlawful.</p>\n<p><b>About Bright Minds</b>Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bright Minds Biosciences Announces Application to List on Nasdaq</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBright Minds Biosciences Announces Application to List on Nasdaq\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18565519><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18565519\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QID":"纳指两倍做空ETF","PSQ":"纳指反向ETF","NDAQ":"纳斯达克OMX交易所","SQQQ":"纳指三倍做空ETF","BMBIF":"Bright Minds Biosciences Inc.",".IXIC":"NASDAQ Composite","QLD":"纳指两倍做多ETF","QQQ":"纳指100ETF"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18565519","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143795927","content_text":"VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain, is pleased to announce that it has submitted an application to list on The Nasdaq Stock Market (“Nasdaq”). The Company has reserved the right to trade under the symbol “DRUG.”\nCommenting on the plans for the Nasdaq listing, Ian McDonald, Chief Executive Officer of Bright Minds, said, “We believe that this is an ideal time for Bright Minds to announce its plans to move to a leading national stock exchange. Serotonergic therapeutics have gained considerable traction and are on the cusp of an exciting revolution in medicine. BMB is already moving to the clinic with a patented 5-HT2C drug for use in epilepsy. Moreover, having developed a robust pipeline of novel, best-in-class 5-HT2A/2C (serotonin) agonists that refine and build on the first-generation natural compound approaches, Bright Minds has laid a solid foundation to become the front runner in psychedelic-drug inspired medicine. We are very excited to list on the Nasdaq and see it as a critical step in our evolution as a public company. The additional capital markets exposure will elevate our company profile with the biotechnology investment community, broaden and diversify our investor base, and most importantly, continue to support our efforts to design and develop next-generation therapeutics that address difficult-to-treat indications across mental health disorders, epilepsy and pain management.”\nIn advance of an anticipated listing on Nasdaq, Bright Minds has filed a Registration Statement with the United States Securities and Exchange Commission. The listing of Common Shares on Nasdaq remains subject to the review and approval of the listing application and the satisfaction of all applicable listing and regulatory requirements, as well as the effectiveness of the registration statement. Bright Minds will continue to maintain the listing of its Shares on the Canadian Stock Exchange under the symbol “DRUG.”\nBright Minds also announced that it has granted an aggregate of 180,000 stock options (the “Options”) to a director and a consultant of the Company to purchase 180,000 common shares (the “Shares”) in the capital of the Company pursuant to the Company’s share option plan. The Options are exercisable at an exercise price of $7.60 per Share for a period of five (5) years from the date of grant. The Options are subject to vesting periods over the course of the term of the Options.\nThe securities of the Company referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation, or sale would be unlawful.\nAbout Bright MindsBright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.","news_type":1},"isVote":1,"tweetType":1,"viewCount":260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172623653,"gmtCreate":1626959806072,"gmtModify":1633769379648,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/172623653","repostId":"2153678132","repostType":4,"repost":{"id":"2153678132","pubTimestamp":1626958620,"share":"https://www.laohu8.com/m/news/2153678132?lang=&edition=full","pubTime":"2021-07-22 20:57","market":"us","language":"en","title":"How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2153678132","media":"Motley Fool","summary":"There are four possible answers.","content":"<p><b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> currently has <a href=\"https://laohu8.com/S/AONE.U\">one</a> product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of which will advance into late-stage clinical studies this year</p>\n<p><b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.</p>\n<p>Pfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.</p>\n<p>Now for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?</p>\n<p><img src=\"https://static.tigerbbs.com/87bb195f09ece4498c77c8942205e5a8\" tg-width=\"700\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Four possibilities</h3>\n<p>There are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:</p>\n<ol>\n <li>Moderna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.</li>\n <li>Moderna stock is overvalued.</li>\n <li>Pfizer stock is undervalued.</li>\n <li>Both No. 2 and No. 3 above are true.</li>\n</ol>\n<p>If you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.</p>\n<p>Some investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.</p>\n<p>My view is similar to the one held by Warren Buffett's mentor, Benjamin <a href=\"https://laohu8.com/S/GHC\">Graham</a>. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.</p>\n<h3>The best answer</h3>\n<p>I have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the <b>S&amp;P 500</b> average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.</p>\n<p>Part of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.</p>\n<p>The key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.</p>\n<p>However,&nbsp;I suspect that investors could be overly exuberant about the company's inclusion on the S&amp;P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.</p>\n<p>In my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.</p>\n<h3>A temporary situation</h3>\n<p>When a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.</p>\n<p>On the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.</p>\n<p>I don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153678132","content_text":"Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, one of which will advance into late-stage clinical studies this year\nPfizer is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.\nPfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.\nNow for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?\n\nImage source: Getty Images.\nFour possibilities\nThere are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:\n\nModerna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.\nModerna stock is overvalued.\nPfizer stock is undervalued.\nBoth No. 2 and No. 3 above are true.\n\nIf you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.\nSome investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.\nMy view is similar to the one held by Warren Buffett's mentor, Benjamin Graham. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.\nThe best answer\nI have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the S&P 500 average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.\nPart of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.\nThe key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.\nHowever, I suspect that investors could be overly exuberant about the company's inclusion on the S&P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.\nIn my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.\nA temporary situation\nWhen a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.\nOn the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.\nI don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170402048,"gmtCreate":1626444496184,"gmtModify":1633926680652,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/170402048","repostId":"1119997447","repostType":4,"isVote":1,"tweetType":1,"viewCount":113,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":131418321,"gmtCreate":1621873093863,"gmtModify":1634185888751,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/131418321","repostId":"2137153015","repostType":4,"isVote":1,"tweetType":1,"viewCount":250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":100439171,"gmtCreate":1619627192393,"gmtModify":1634211204688,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Mm","listText":"Mm","text":"Mm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/100439171","repostId":"1104198438","repostType":4,"isVote":1,"tweetType":1,"viewCount":370,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":100430961,"gmtCreate":1619627089353,"gmtModify":1634211205061,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/100430961","repostId":"1196474090","repostType":4,"isVote":1,"tweetType":1,"viewCount":268,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":376955276,"gmtCreate":1619083157295,"gmtModify":1634288694301,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"H","listText":"H","text":"H","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/376955276","repostId":"1134663439","repostType":4,"repost":{"id":"1134663439","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1619082614,"share":"https://www.laohu8.com/m/news/1134663439?lang=&edition=full","pubTime":"2021-04-22 17:10","market":"us","language":"en","title":"Why Square And Cathie Wood's Ark See Bitcoin Environmental Concerns As Unfounded","url":"https://stock-news.laohu8.com/highlight/detail?id=1134663439","media":"Benzinga","summary":"Cathie Wood-led Ark Investment Management and digital payment company Square Inc.(NYSE:SQ) have team","content":"<p>Cathie Wood-led&nbsp;<b>Ark Investment Management</b>&nbsp;and digital payment company&nbsp;<b>Square Inc.</b>(NYSE:SQ) have teamed up to dispel the notion thatBitcoin(BTC) mining is damaging the environment.</p><p><b>What Happened:</b>&nbsp;Ark Investment and Jack Dorsey-led Squarereleaseda whitepaper arguing that Bitcoin mining provides an opportunity to spur the global energy transition to renewables by serving as a complementary technology for clean energy production and storage.</p><p>“Combining generation with both storage and miners presents a better overall value proposition than building generation and storage alone,” the companies noted.</p><p>The companies believe that Bitcoin miners as a flexible and easily interruptible load option could likely solve the intermittency and grid congestion problems hampering the deployment of solar and wind energy, which are now the cheapest energy sources in the world.</p><p>The combination of miners with renewable and storage projects could improve the returns for project investors, allow for the construction of solar and wind projects even before the completion of lengthy grid interconnection studies, and provide the grid with readily available “excess” energy, according to the paper.</p><p>“The bitcoin and energy markets are converging and we believe the energy asset owners of today will likely become the miners of tomorrow,” the companies concluded.</p><p>Square is heavily invested&nbsp;in Bitcoin.&nbsp;Cathie Wood is also bullish on cryptocurrencies and hasacquired sharesin cryptocurrency exchange<b>Coinbase Global Inc.</b>(NASDAQ:COIN), which recently made its debut on the Nasdaq stock exchange.</p><p><b>Why It Matters:</b>&nbsp;The release of the research paper comes amid arguments that Bitcoin causes tons of carbon emissions and environmental degradation<b>.</b></p><p>Bank of America analyst Francisco Blanchcriticized Bitcoin&nbsp;in March, noting that the Bitcoin network emits about 60 million tons of CO2 annually, roughly the same carbon footprint as the nation of Greece.</p><p>For every $1 billion of fresh inflow into bitcoin, Blanch estimates the cryptocurrency will generate additional CO2 levels equivalent to about 1.2 million cars with internal combustion engines.</p><p><b>Microsoft Corporation</b>&nbsp;(NASDAQ:MSFT) founder Bill Gates has also expressed concerns about Bitcoin’s impact on climate change,notingin February that the cryptocurrency “uses more electricity per transaction than any other method known to mankind.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Square And Cathie Wood's Ark See Bitcoin Environmental Concerns As Unfounded</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Square And Cathie Wood's Ark See Bitcoin Environmental Concerns As Unfounded\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-04-22 17:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Cathie Wood-led&nbsp;<b>Ark Investment Management</b>&nbsp;and digital payment company&nbsp;<b>Square Inc.</b>(NYSE:SQ) have teamed up to dispel the notion thatBitcoin(BTC) mining is damaging the environment.</p><p><b>What Happened:</b>&nbsp;Ark Investment and Jack Dorsey-led Squarereleaseda whitepaper arguing that Bitcoin mining provides an opportunity to spur the global energy transition to renewables by serving as a complementary technology for clean energy production and storage.</p><p>“Combining generation with both storage and miners presents a better overall value proposition than building generation and storage alone,” the companies noted.</p><p>The companies believe that Bitcoin miners as a flexible and easily interruptible load option could likely solve the intermittency and grid congestion problems hampering the deployment of solar and wind energy, which are now the cheapest energy sources in the world.</p><p>The combination of miners with renewable and storage projects could improve the returns for project investors, allow for the construction of solar and wind projects even before the completion of lengthy grid interconnection studies, and provide the grid with readily available “excess” energy, according to the paper.</p><p>“The bitcoin and energy markets are converging and we believe the energy asset owners of today will likely become the miners of tomorrow,” the companies concluded.</p><p>Square is heavily invested&nbsp;in Bitcoin.&nbsp;Cathie Wood is also bullish on cryptocurrencies and hasacquired sharesin cryptocurrency exchange<b>Coinbase Global Inc.</b>(NASDAQ:COIN), which recently made its debut on the Nasdaq stock exchange.</p><p><b>Why It Matters:</b>&nbsp;The release of the research paper comes amid arguments that Bitcoin causes tons of carbon emissions and environmental degradation<b>.</b></p><p>Bank of America analyst Francisco Blanchcriticized Bitcoin&nbsp;in March, noting that the Bitcoin network emits about 60 million tons of CO2 annually, roughly the same carbon footprint as the nation of Greece.</p><p>For every $1 billion of fresh inflow into bitcoin, Blanch estimates the cryptocurrency will generate additional CO2 levels equivalent to about 1.2 million cars with internal combustion engines.</p><p><b>Microsoft Corporation</b>&nbsp;(NASDAQ:MSFT) founder Bill Gates has also expressed concerns about Bitcoin’s impact on climate change,notingin February that the cryptocurrency “uses more electricity per transaction than any other method known to mankind.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134663439","content_text":"Cathie Wood-led Ark Investment Management and digital payment company Square Inc.(NYSE:SQ) have teamed up to dispel the notion thatBitcoin(BTC) mining is damaging the environment.What Happened: Ark Investment and Jack Dorsey-led Squarereleaseda whitepaper arguing that Bitcoin mining provides an opportunity to spur the global energy transition to renewables by serving as a complementary technology for clean energy production and storage.“Combining generation with both storage and miners presents a better overall value proposition than building generation and storage alone,” the companies noted.The companies believe that Bitcoin miners as a flexible and easily interruptible load option could likely solve the intermittency and grid congestion problems hampering the deployment of solar and wind energy, which are now the cheapest energy sources in the world.The combination of miners with renewable and storage projects could improve the returns for project investors, allow for the construction of solar and wind projects even before the completion of lengthy grid interconnection studies, and provide the grid with readily available “excess” energy, according to the paper.“The bitcoin and energy markets are converging and we believe the energy asset owners of today will likely become the miners of tomorrow,” the companies concluded.Square is heavily invested in Bitcoin. Cathie Wood is also bullish on cryptocurrencies and hasacquired sharesin cryptocurrency exchangeCoinbase Global Inc.(NASDAQ:COIN), which recently made its debut on the Nasdaq stock exchange.Why It Matters: The release of the research paper comes amid arguments that Bitcoin causes tons of carbon emissions and environmental degradation.Bank of America analyst Francisco Blanchcriticized Bitcoin in March, noting that the Bitcoin network emits about 60 million tons of CO2 annually, roughly the same carbon footprint as the nation of Greece.For every $1 billion of fresh inflow into bitcoin, Blanch estimates the cryptocurrency will generate additional CO2 levels equivalent to about 1.2 million cars with internal combustion engines.Microsoft Corporation (NASDAQ:MSFT) founder Bill Gates has also expressed concerns about Bitcoin’s impact on climate change,notingin February that the cryptocurrency “uses more electricity per transaction than any other method known to mankind.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":332,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887583775,"gmtCreate":1632064306797,"gmtModify":1632803059679,"author":{"id":"3580907067323762","authorId":"3580907067323762","name":"NgJacqi","avatar":"https://static.tigerbbs.com/1ed030351dab6e6ab6b31fa6606c2e46","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580907067323762","idStr":"3580907067323762"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/887583775","repostId":"2153678132","repostType":4,"repost":{"id":"2153678132","pubTimestamp":1626958620,"share":"https://www.laohu8.com/m/news/2153678132?lang=&edition=full","pubTime":"2021-07-22 20:57","market":"us","language":"en","title":"How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2153678132","media":"Motley Fool","summary":"There are four possible answers.","content":"<p><b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> currently has <a href=\"https://laohu8.com/S/AONE.U\">one</a> product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of which will advance into late-stage clinical studies this year</p>\n<p><b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.</p>\n<p>Pfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.</p>\n<p>Now for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?</p>\n<p><img src=\"https://static.tigerbbs.com/87bb195f09ece4498c77c8942205e5a8\" tg-width=\"700\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Four possibilities</h3>\n<p>There are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:</p>\n<ol>\n <li>Moderna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.</li>\n <li>Moderna stock is overvalued.</li>\n <li>Pfizer stock is undervalued.</li>\n <li>Both No. 2 and No. 3 above are true.</li>\n</ol>\n<p>If you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.</p>\n<p>Some investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.</p>\n<p>My view is similar to the one held by Warren Buffett's mentor, Benjamin <a href=\"https://laohu8.com/S/GHC\">Graham</a>. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.</p>\n<h3>The best answer</h3>\n<p>I have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the <b>S&amp;P 500</b> average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.</p>\n<p>Part of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.</p>\n<p>The key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.</p>\n<p>However,&nbsp;I suspect that investors could be overly exuberant about the company's inclusion on the S&amp;P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.</p>\n<p>In my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.</p>\n<h3>A temporary situation</h3>\n<p>When a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.</p>\n<p>On the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.</p>\n<p>I don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/22/how-in-the-world-is-moderna-valued-at-more-than-ha/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153678132","content_text":"Moderna, Inc. currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. The company also has 14 other pipeline candidates, one of which will advance into late-stage clinical studies this year\nPfizer is Moderna's chief rival in the COVID-19 vaccine market. The drugmaker had half-a-dozen products that generated more than $1 billion in sales last year -- and that doesn't include its COVID-19 vaccine. It has scores of other products, too.\nPfizer will probably rake in well over $70 billion this year. Its pipeline includes nearly 100 clinical programs, 25 of which are either awaiting regulatory approval or in late-stage testing.\nNow for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion. How in the world is Moderna valued at more than half of Pfizer's market cap?\n\nImage source: Getty Images.\nFour possibilities\nThere are basically four possible answers as to why Moderna is more than half the size of Pfizer right now:\n\nModerna really deserves to be roughly half the size of Pfizer because of its stronger growth prospects.\nModerna stock is overvalued.\nPfizer stock is undervalued.\nBoth No. 2 and No. 3 above are true.\n\nIf you're a believer in the efficient market hypothesis (EMH), No. 1 is the correct answer. This hypothesis maintains that share prices reflect all available information at the time. Assuming EMH is right, both Moderna and Pfizer are fairly valued based on what can be known about the companies and their prospects.\nSome investors think the EMH doesn't hold water in the real world, though. If they're right, any of the other three possibilities could be on target.\nMy view is similar to the one held by Warren Buffett's mentor, Benjamin Graham. Sometimes, the market behaves rationally and stocks are fairly valued. At other times, though, the market is decidedly irrational, resulting in stocks being mispriced. I don't think the market is being completely rational with the valuations of Moderna and Pfizer.\nThe best answer\nI have been on record for a while now that Pfizer is undervalued. The company's shares trade at only 11 times expected earnings, which is a lot cheaper than the S&P 500 average forward earnings multiple. It's also below the average forward price-to-earnings (P/E) ratio for pharmaceutical stocks.\nPart of the reason behind Pfizer's relatively low valuation is that several of its top products lose exclusivity beginning in 2025. However, I think that focusing just on this misses the bigger picture that includes Pfizer's pipeline, the potential for its COVID-19 vaccine to generate strong recurring sales, and the possibility that the company makes acquisitions that drive growth.\nThe key question is whether or not Moderna is also overvalued. My view is that Moderna's messenger RNA (mRNA) platform gives the company tremendous growth potential over the long term. The biotech stock doesn't appear to be priced at a premium based on its forward earnings multiple of a little under 13.\nHowever, I suspect that investors could be overly exuberant about the company's inclusion on the S&P 500 index. And I think it's still too soon to know just how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine. Factoring in this uncertainty, my view is that the stock has risen too much too soon.\nIn my opinion, there's one best answer to the question about how Moderna could be valued at more than half the size of Pfizer: Moderna is overvalued, while Pfizer is undervalued.\nA temporary situation\nWhen a stock's valuation is out of whack, it won't remain that way indefinitely. If I'm right, Moderna's share price will decline at some point, while Pfizer's will increase. The current scenario where Moderna is valued at more than half of Pfizer's market cap should be only temporary.\nOn the other hand, the uncertainty about the recurring revenue for COVID-19 vaccines will be resolved in the not-too-distant future, as well. Moderna's pipeline will expand. I fully expect the company will have more mRNA vaccines on the market within the next few years.\nI don't think that Moderna is worth $120 billion or more right now. My opinion -- like Moderna's overvaluation and Pfizer's undervaluation -- is only temporary, though. It wouldn't surprise me at all if Moderna grows into a much larger company over the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}